GLIPR1 and glioblastoma: Using the TCGA data [27], we also found that patients with GBM expressing low levels of RTVP-1 have a significantly prolonged disease-free survival compared to patients with tumors expressing high levels of this protein (1062 days vs. 333 days, P = 0.00014) (Fig. 1D).